
Heath Law Alliance is proud to announce a major legal victory on behalf of its pharmacy client in California: the full reversal of a Medi-Cal (California Medicaid) payment suspension imposed by the California Department of Health Care Services (DHCS).
Medi-Cal payment suspensions are serious administrative actions that can jeopardize a pharmacy’s business operations, reputation, and its ability to service its patients. These payment suspensions are often triggered by preliminary audit findings and/or other unverified suspicions of wrongdoing. In this case, DHCS initiated a payment suspension based on speculative allegations and incomplete evidence.
Heath Law Alliance intervened immediately. Our legal team crafted a number of strategic and persuasive appeals, demonstrating that the Department’s allegations failed to meet the legal standards required under both state and federal law. After a thorough review, the Office of Administrative Hearings and Appeals agreed with our position and issued a decision reversing the payment suspension in full.
This outcome underscores the importance of experienced legal counsel when dealing with Medicaid and/or any other insurance payors. It highlights our firm’s commitment to aggressive advocacy and unwavering defense of healthcare providers’ rights and business operations.
How Health Law Alliance Can Help
If your pharmacy is facing insurance payment suspensions, network terminations, investigations, and/or PBM audits, Heath Law Alliance stands ready to defend your practice and challenge unjust enforcement actions. With extensive experience in healthcare law, Medicaid and Medicare regulations, pharmacy provider defense, and litigation, our law firm is uniquely positioned to safeguard your interests and help secure the future of your pharmacy business.
Contact us today to schedule a free consultation.
MORE ARTICLES BY CATEGORY
The 2025 Healthcare Fraud Takedown Is a Warning Shot for Wound Care Providers
Wound care is now an enforcement priority. The 2025 fraud takedown targets skin substitute billing, graft utilization, and Medicare compliance.
Read More >>FDA and Novo’s Uncharted Waters to Exert Pressure on Hims & Hers and GLP-1 Compounders
Novo’s lawsuit against Hims & Hers, coupled with FDA’s referral to the DOJ, marks a direct escalation against 503A compounded semaglutide. If your pharmacy dispenses, compounds, or markets GLP-1 therapies, this is not a headline, it is a regulatory turning point.
Read More >>What Wells Pharma v. Zyla Life Sciences Means for Compounding Pharmacies and Outsourcing Facilities
A pending Supreme Court case could reshape how compounding pharmacies face litigation under state unfair competition laws tied to FDA approval standards.
Read More >>Health Law Alliance Welcomes Compounding Expert Pharmacist-Attorney Dr. Martha Rumore as Of Counsel
Health Law Alliance adds powerhouse Pharmacist/Attorney Dr. Martha Rumore to their team of boutique healthcare attorneys.
Read More >>





